Advanced Search
Contact | Corporate | Help

Irinotecan and Bevacizumab for Recurrent Ovarian Cancer

Sponsors:
  • New York University School of Medicine
  • Genentech
Phases:
  • Phase II
IndicationsAcronym:
  • Ovarian Cancer
Age Groups:
  • Adult
  • Senior
Gender:
Female
Names:
  • Drug: Bevacizumab
Enrollment:
45

Additional information about NCT01091259.


SourceSolution © 2008-2012